Introduction
============

Recruitment of lymphocytes in a tissue-specific fashion is, on the one hand, a requirement for immune surveillance and defense against pathogens and tumors, but, on the other hand, plays a key role in the pathogenesis of inflammatory diseases, such as psoriasis, eczematous disorders, drug-induced eruptions, or lichen planus of the skin ([@b35]; [@b65]). Consequently, insight into mechanisms of leukocyte recruitment to the skin is essential not only for our understanding of the pathophysiology of inflammatory skin disorders, but also for the development of novel and selective therapies to treat such diseases, which heavily impact quality of life as well as the economic burden of healthcare systems worldwide. Given that the first steps of tissue-selective trafficking of leukocytes are mediated primarily by selectins, these molecules are being explored as promising therapeutic target structures.

Tethering and rolling of leukocytes: the selectin-mediated first contact to the vessel wall
===========================================================================================

The first steps of leukocyte localization to all tissues include tethering and rolling along the vessel wall ([Figure 1](#fig1){ref-type="fig"}) -- rather loose and transient adhesive interactions that are essential for the subsequent firm adhesion, activation, and transmigration ([@b81]). Members of the selectin family of adhesion molecules are the primary mediators of these initial contacts ([@b34]; [@b69]; [@b80]; [@b73]; [@b75]; [@b18]). Selectins are single-chain transmembrane adhesion molecules, which have been named for their lectin-like domain that attaches to carbohydrate ligands presented on glycoprotein scaffolds ([@b79]; [@b28]; [@b54]). Three selectins have been described: E- and P-selectin are expressed by endothelial cells, and L-selectin is expressed by leukocytes. E-selectin (CD62E) is primarily regulated on the transcriptional level and is strongly induced upon activation of endothelial cells by proinflammatory stimuli ([@b23]; [@b11]). In contrast, P-selectin (CD62P) is rapidly mobilized to the cell surface from its storage vesicles, the cytoplasmic Weibel-Pallade bodies, upon activation of endothelial cells ([@b17]; [@b60]). In addition, there is some transcriptional regulation of P-selectin ([@b78]). The pivotal role of P- and E-selectin for lymphocyte rolling has been demonstrated in a large variety of experimental approaches interfering with adhesive interactions of selectins and their carbohydrate ligands ([@b19]; [@b77]). Of note, several studies have demonstrated considerably overlapping and mutually compensating functions of the selectin family members, a finding that raises important consequences and constraints for the rational design of selectin-blocking drugs ([@b53]; [@b47]; [@b83]; [@b21]). Consistent with these studies, a function-blocking antibody specifically directed against E-selectin did not significantly alleviate psoriasis, one of the most common chronic inflammatory skin disorders, in a clinical trial ([@b12]). Likewise, specifically blocking L-selectin in a recent controlled clinical trial has failed to improve psoriatic lesions ([@b39]). These observations in clinical settings have strongly supported and complemented the results from experimental studies showing that some selectin-mediated functions may be redundant and that interfering with a single selectin alone is not sufficient to interrupt the inflammatory chains in some inflammatory diseases. This notion is further corroborated by several small-molecule compounds that interfere with the functions of more than one selectin. The list of such compounds includes efomycine M, a non-carbohydrate macrolide inhibitor of both E- and P-selectin functions. Blocking both E- and P-selectin by efomycine M significantly diminished rolling of leukocytes on cutaneous microvessels and markedly alleviated chronic inflammatory skin conditions in a T cell-mediated murine model of psoriasis as well as in human psoriatic skin transplanted onto *scid/scid* mice ([@b67]). Another promising example exhibiting broader activity against all three known selectins is bimosiamose, a compound that appeared to be efficacious in early clinical trials ([@b6]; [@b43]). Likewise, broader clinical efficacy may be expected from some other recently described compounds interfering with the functions of more than one selectin ([@b16]; [@b78]).

![Molecular interactions involved in lymphocyte extravasation in the skin (modified from [@b81]; [@b16]). The upper part of the figure depicts key steps of interactions with the endothelial lining resulting in extravasation of lymphocytes. The bottom part shows selected adhesion molecules which mediate these events.](tcrm0103-201-f1){#fig1}

The lymphocyte-expressed L-selectin (CD62L) binds to endothelial cell selectin ligands ([Figure 1](#fig1){ref-type="fig"}). Although some of its ligands, such as PNAd (Peripheral Node Addressin), may be induced in chronic inflammatory skin disorders, the contribution of L-selectin to cutaneous recruitment of lymphocytes appears to be limited due to its preferential expression by naive and a subpopulation of memory T cells rather than activated T cells. Thus, it has been proposed that L-selectin/PNAd interactions may be more important for extravasation of naive T cells in lymph nodes ([@b82]; [@b55]), a prerequisite for the priming of naive T lymphocytes. The topographic distribution of L-selectin at the tips of microvilli of rolling lymphocytes is thought to be important for easy contact formation with endothelial ligands ([@b30]). Following ligand binding, L-selectin is shed from the cell surface at the trailing edge of rolling lymphocytes. The shedding of L-selectin is a proteolytic process mediated by metalloproteases ([@b22]; [@b85]). It is thought that shedding is required for proper lymphocyte rolling ([@b37]), since inhibition of L-selectin shedding resulted in increased LFA-1/ICAM-1-mediated firm adhesion and, consecutively, transmigration of lymphocytes ([@b38]), supporting the hypothesis of a regulatory function of the shedding process.

In addition to the expression of L-selectin, lymphocytes express transmembrane glycoproteins bearing Sialyl-Lewis^X^ (sLe^X^) moieties, that function as E- and P-selectin ligands ([@b79]). Among these ligands, the sLe^X^-bearing CLA (cutaneous lymphocyte-associated antigen), a specially glycosylated form of PSGL-1 (P-selectin glycoprotein ligand-1, CD162) ([@b31]), is preferentially expressed by lymphocytes localizing to the skin. Accumulating experimental evidence has been published demonstrating that CLA is indeed functionally involved in tissue-specific recruitment to this organ ([@b63], [@b62]). Topographic specialization of microvascular endothelial cells within the skin is suggested by the observation that CLA-bearing T lymphocytes appear to extravasate preferentially through the endothelium of the superficial dermal plexus ([@b52]), a cutaneous compartment potentially accessible for topically applied selectin inhibitors.

Selectin-mediated rolling of lymphocytes is complemented by VLA-4 (very late-activation antigen-4, CD49d/CD29), a heterodimeric adhesion receptor of the integrin family that binds to VCAM-1 (vascular cell adhesion molecule-1) and MAdCAM-1 (mucosal addressin cell adhesion molecule-1), two members of the immunoglobulin (Ig) superfamily of adhesion molecules ([Figure 1](#fig1){ref-type="fig"}). It has been reported that VLA-4 also mediates rolling of leukocyte subsets under certain conditions ([@b10]; [@b64]; [@b72]). It is thought that its involvement in lymphocyte rolling is due, at least in part, to the topographic presentation of VLA-4 on microvilli of rolling cells, similar to the decoration of Lselectin, thus enabling easy contact formation with endothelial cell-expressed counter-receptors ([@b10]). The ligand binding affinity of VLA-4 can be rapidly up-regulated via the p56^lck^ Src kinase signaling pathway following T lymphocyte stimulation ([@b27]). This rapid change in integrin activity is thought to be crucial for the transition from rolling to firm adhesion of lymphocytes. While some aspects of the interplay of VLA-4- and selectin-mediated adhesive interactions involved in lymphocyte rolling still remain to be unraveled, it appears that there is some redundancy in their functions. In cutaneous inflammation in rats, all three receptors, E-selectin, P-selectin, and VLA-4, are apparently required for rolling of memory T lymphocytes ([@b46]). It is possible that tissue-specific (micro)-environmental factors regulate their relative contributions to lymphocyte recruitment. In addition to VLA-4, the integrin LFA-1 has been reported to mediate neutrophil rolling under certain conditions ([@b41]), and both VLA-4 and LFA-1 can mediate selectin-independent recruitment of neutrophils and monocytes to sites of chronic inflammation ([@b15]). Fractalkine may be another player contributing to endothelial capture and firm adhesion of leukocytes without an involvement of selectins ([@b29]; [@b40]).

Finally, in addition to rolling of lymphocytes through direct contact to the endothelial lining, recent research has highlighted the importance of platelets for rolling under certain conditions ([@b51]; [@b56]). While P-selectin has been implicated in adhesive interactions of platelets and leukocytes, the exact contribution of this process to cutaneous inflammation has not been completely defined yet ([@b32]; [@b57]).

Selectins as molecular targets for antiinflammatory therapies
=============================================================

Given that selectins mediate the critical first step in the cascade of leukocyte recruitment during inflammatory responses, it is not surprising that these molecules have received much attention as potential target structures for selective and specific therapies. Indeed, few areas in biomedical and pharmaceutical research reflect the excitement and enthusiasm, but also a number of drawbacks and disappointments associated with new developments as vividly as selectin-directed antiinflammatory strategies targeting lymphocyte extravasation. Indeed, as they appear to meet the "desire" for a mechanistic basis of diseases and, consecutively, rational therapeutic strategies, selectins are appealing target structures ([@b16]; [@b16]). This is reflected by a variety of selectin-directed agents including small-molecule compounds, carbohydrate mimetics, and antibodies generated by several companies to treat inflammatory disorders (synopsis shown in [Table 1](#tbl1){ref-type="table"}). However, a closer look at the complex and intertwined molecular crosstalk underlying lymphocyte recruitment may dampen some illusions or dishearten overenthusiastic approaches. In addition, recruitment to inflamed tissues may be tightly connected with other cellular functions of immunocytes such as chemokine receptor-mediated activation that follows selectin-mediated adhesion. As a consequence, inflammatory diseases encountered by clinicians are rarely predictable from single molecular pathways, and the design or selection of compounds targeting specific molecules involved in the inflammatory cascade is often difficult and may face considerable imminent problems ([@b48]). This is reflected by the fact that some of the programs searching for inhibitors of the selectin family have been stopped for the indication of inflammatory disorders ([Table 1](#tbl1){ref-type="table"}), a notion that may reflect inherent difficulties in targeting this very initial step of leukocyte recruitment.

###### 

Selectin-directed compounds developed for the treatment of inflammatory disorders

  Target              Compound      Company                       Status        Reference
  ------------------- ------------- ----------------------------- ------------- -------------------------------
  Selectins           CY-1503       Cytel Corp                    Preclinical   [@b49]
  Selectins           BMS-190394    BMS                           Preclinical   [@b14]
  Selectins                         Aventis                       Preclinical   [@b59]
  Selectins           OC-229648     Ontogen Kanebo                Preclinical   
  Selectins           efomycine M   none                          Preclinical   [@b67]
  E-selectin          ESA-2         Novartis                      Preclinical   [@b76]; [@b7]; [@b38]; [@b13]
  Selectins           OJ- R9188     Nippon Organon                Preclinical   [@b45]
  Selectins           TBC-1269      Texas Biotechnology Revotar   Phase I/II    [@b1]; [@b4]
  E- and P-selectin   PS3           None                          Preclinical   [@b84]
  E- and P-selectin   EP-5C7        Protein Design Labs           Phase I       [@b8]; [@b2]
  E- and L-selectin   EL-246        LygoCyte                      Preclinical   [@b20]
  E-selectin          CDP-850       Celltech                      Phase II      [@b12]
  P-selectin          rhPSGL-1 Ig   Genetics Institute            Phase II      [@b50]
  L-selectin          LD201t1       WyethNeXStar                  Preclinical   [@b42]

Overall, there are several challenges that may make approaches to target molecules involved in leukocyte recruitment very complex and unpredictable, and this is mirrored by the fact that some of the previous approaches were not satisfying in preclinical or clinical trials. This includes trials using the sialyl Lewis^X^-mimetic Cylexin ([@b49]), an anti E-selectin-directed monoclonal antibody ([@b12]), or a L-selectin-directed antibody ([@b39]). Several reasons, which are not mutually exclusive, can be delineated:

1.  Specificity for only one selectin or a suboptimal combination of selectin specificities;

2.  Low IC~50~ values;

3.  Short half-lives or other unfavorable pharmacokinetic properties; or

4.  Lability of selectin--selectin ligand interaction, which is essential for short-lived lymphocyte--endothelial interactions.

So, what are the challenges that we are facing? Perhaps the most important reason for the limited predictability of antiinflammatory approaches through targeting selectins is *functional redundancy*; ie, as outlined above, selectins may have considerable functional overlaps. In particular, this is true for endothelial E- and P-selectin ([@b53]; [@b47]; [@b21]), allowing them to compensate for each other in case of loss of function of one of the players. While prominent examples have been reported in the selectin field ([@b53]; [@b47]; [@b21]), this problem is by no means unique to this family, since similar (maybe even more pronounced) redundancy problems are faced when targeting the chemokine/chemokine receptor system ([@b86]; [@b61]).

It was long believed that CLA expressed by skin-homing T cells is mainly an E-selectin ligand ([@b9]; [@b66]). However, the carbohydrate moieties mediating tethering and rolling of lymphocytes along the endothelial lining also bind to P- and L-selectin ([@b53]; [@b47]; [@b21]). Activated endothelial cells in inflamed tissues may express PNAd, a ligand for lymphocyte-expressed L-selectin, although L-selectin itself is not expressed by endothelial cells. This mechanism may compensate for lymphocyte rolling when E- and P-selectin are selectively blocked, eg, by small-molecule- or antibody-based therapeutics ([@b3]; [@b26]). In addition, T cells may roll along the vessel wall through cluster formation with activated platelets ([@b25], [@b24]; [@b57]), and even in the complete absence of selectins and their ligands, rolling of some lymphocytes may occur through interactions of endothelial VCAM-1 with the lymphocyte-expressed VLA-4 integrin ([@b47]). Similar problems may be encountered when glycosylation of selectin ligands is targeted, eg, by proteasome inhibitors ([@b87]). Rational drug design of compounds modeled after functionally relevant groups, or high-throughput screenings assessing the functions of single molecules as readout parameters might, therefore, confront the aforesaid problems.

Recent examples of approaches that may have been too specific (thus neglecting functional redundancy) include the failure of antibodies directed specifically against E-selectin or L-selectin to alleviate psoriasis in controlled clinical trials ([@b12]; [@b39]), or the limited clinical response to recombinant human (rh) PSGL-1 Ig ([@b50]). In that respect, concepts interfering with a group of molecules with overlapping functions involved in a given step of lymphocyte extravasation may bear some advantages, such as efomycine M or the TBC-1269 compound (bimosiamose) blocking several selectins ([@b1]; [@b67]). However, the success of such broader strategies is not guaranteed, as exemplified by the insufficient response to the pan-selectin inhibitor OJ-R9188 ([@b45]).

Another group of potential problems relates to *unexpected effects*; ie, targeting of certain molecules may result in unexpected or even paradoxical outcomes. As a possible example, a regulatory effect of chemokines on lymphocyte rolling has recently been identified, inasmuch as chemokines may exert (paradoxical) antiadhesive effects through G-protein-independent destabilization of L-selectin ([@b33]).

An alternative or additional approach to target leukocyte rolling along the skin microvasculature through modulation of selectin functions is interference with fucosyltransferase(FucT)-VII and -IV, key enzymes in the generation of selectin-ligand carbohydrate moieties. The rationale behind this approach comes from the observation that selectin ligand activity is absent or reduced dramatically in FucT-VII single or FucT-IV and -VII double knockout mice. Cutaneous inflammatory responses are markedly reduced in several models of inflammatory diseases using animals deficient for one or both enzymes ([@b58]; [@b83]; [@b44]; [@b5]). The relevance of this impaired function in human patients is highlighted by leukocyte adhesion deficiency II (LAD II), a rare congenital immune defect ([@b36]). One potential approach to interfere with expression of FucT-VII is inhibiting its transcription using NF-κB inhibitors such as the proteasome inhibitor PS-519 or antioxidants such as N-acetyl cysteine ([@b87]). However, given that interfering with the pleiotropic effects of NF-κB may have many other effects on the immune system and other cells, the low specificity of this approach is a potential disadvantage. Another strategy might encompass the inhibition of FucT activity by small-molecule compounds. As posttranslational glycosylation of proteins by FucTs occurs in the Golgi apparatus, it might, however, be challenging to identify small molecules penetrating both the cell membrane and the Golgi membrane. At least two different companies (GlaxoSmithKline, Kyowa Hakko Kogyo) have reported recombinant expression of FucT-VII protein ([@b70]; [@b74]), suggesting that this latter approach has been pursued. In addition, panosialins A and B have been isolated as inhibitors of FucTVII from the culture broth of *Streptomyces sp*., which inhibit FucT-VII activity and cell binding to immobilized selectin ligands in vitro ([@b71]).

Overall, it is generally not easy to predict the clinical feasibility and efficacy of selectively targeting selectin functions in the treatment of inflammatory disorders. It appears that at least two levels of complex interactions influence the success of therapeutic strategies aimed at lymphocyte extravasation; ie, distinct players mediating consecutive pathogenic steps ("vertical", eg, chemokine receptor activation followed by integrin-mediated firm arrest), as well as synchronous action of several molecules mediating a given event ("horizontal", eg, selectins and chemokine receptors simultaneously involved in lymphocyte rolling).
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